Impact of Clonal Heterogeneity in Multiple Myeloma

Carolina Schinke; Leo Rasche; Marc S Raab; Niels Weinhold

doi:10.1016/j.hoc.2023.12.012

Impact of Clonal Heterogeneity in Multiple Myeloma

Hematol Oncol Clin North Am. 2024 Apr;38(2):461-476. doi: 10.1016/j.hoc.2023.12.012. Epub 2024 Jan 8.

Authors

Carolina Schinke¹, Leo Rasche², Marc S Raab³, Niels Weinhold⁴

Affiliations

¹ Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
² Department of Internal Medicine 2, University Hospital of Würzburg, Würzburg, Germany; Mildred Scheel Early Career Center (MSNZ), University Hospital of Würzburg, Würzburg, Germany.
³ Department of Internal Medicine V, Heidelberg University Clinic Hospital, Heidelberg, Germany.
⁴ Department of Internal Medicine V, Heidelberg University Clinic Hospital, Heidelberg, Germany. Electronic address: [email protected].

PMID: 38195308
DOI: 10.1016/j.hoc.2023.12.012

Abstract

Multiple myeloma is characterized by a highly heterogeneous disease distribution within the bone marrow-containing skeletal system. In this review, we introduce the molecular mechanisms underlying clonal heterogeneity and the spatio-temporal evolution of myeloma. We discuss the clinical impact of clonal heterogeneity, which is thought to be one of the biggest obstacles to overcome therapy resistance and to achieve cure.

Keywords: Clonal heterogeneity; Evolution; Microenvironment; Myeloma; Relapse.

Publication types

Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Bone Marrow
Clonal Evolution / genetics
Humans
Multiple Myeloma* / genetics
Multiple Myeloma* / therapy

Grants and funding

P20 GM109005/GM/NIGMS NIH HHS/United States